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A new series of 2,5 and 1,5-regioisomers of the tetrazolyl group viz., 3-[(5-benzyl/benzylthio-2H-tetrazol-
2-yl) methyl]-2-chloro-6-substituted quinoline 6h-q and 3-[(5-benzyl/benzylthio-1H-tetrazol-1-yl)
methyl]-2-chloro-6-substituted quinolines 7h-q were synthesized. Docking studies of all these com-
pounds with DNA as target using PDB: 1AU5 and 453D revealed that the compounds 6h and 6i act as
covalent cross linker on the DNA helix of the former and intercalate the latter both with higher C score
values. Another set of docking studies in the active pocket of dihydrofolate reductase and N-myristoyl
transferase as targets to assess antifungal activity revealed that compounds 6k, 6l, 6p and 7q (with bromo
and ﬂuro substituents) showcases different binding modes and hydrogen bonding. Further, the com-
pounds were screened for anticancer activity (primary cytotoxicity) against NCI-60 Human tumor cell
line at a single high dose (105 M) concentration assay. Among the tested compounds, 6h has shown
99.28% of GI against Melanoma (SK-MEL-5) and compound 6i has shown 97.56% of GI against Breast
Cancer (T-47D). Further, in vitro antifungal assay against A. fumigatus and C. albicans for these compounds
6h-q and 7h-q revealed potential to moderate activities as compared to the standard.
© 2017 Elsevier Masson SAS. All rights reserved.1. Introduction
Cancer is one of the second leading causes of mortality, which is
a great concern of the current century to themankind.Moreover, all
the countries across the globe are being increasingly affected with
this disease. As the populations live longer, the negative lifestyle
and the food habits also increase the cancer risk, which conveys
that cancer can also be termed as lifestyle disease. As per the world
cancer report released by WHO in the forthcoming years the
mortality rates due to cancer will increase twice its current per-
centage [1,2]. Therefore, discovery and development of newer
anticancer agents have become the need and the key focus of many
researchers and pharmaceutical companies. Although earlier re-
ported chemotherapeutic drugs efﬁciently kill cancer cells, but
many times this concludes to develop multi-drug resistance [3].ble).
served.Prevalence of fungal infections is increasing over the past few years
by an increase in cases which are susceptible to such pathogenic
infections. These include patients undergoing chemotherapy for
cancer, malignancies, AIDS or immunosuppressed by afﬂictions,
with high risk of getting fungal infections [4]. However, like bac-
terial infections, some fungi no longer respond to the antifungal
medications which were designed to cure them and most of the
marketed antifungal agents have several drawbacks with respect to
the potency and spectrum of activity. These factors motivate the
researchers to design and develop novel targets with effective
mode of mechanism, more bioactivity and least side effects [5].
Quinoline and its derivatives are considered to be versatile
synthetic modules since they have shown modes of action in the
inhibition of tyrosine kinases; proteasome, tubulin polymerization
and DNA repair [6]. Quinoline nucleus also occurs in several natural
compounds and it is one of the pharmacologically active substances
displaying awide range spectrum of biological activity. The scaffold
can also be found in many classes of biologically active compounds
such as antibacterials, antiprotozoic drugs [7e10], anti-tubercular
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quinoline analogues also showed antiﬁlarial and HIV integrase
inhibitory activities [24,25] which make it to be a valuable scaffold
for many biologically active compounds and several marketed
drugs [26]. Tetrazole, a ﬁve membered heterocycle is considered as
a bioisostere of carboxylic group and is a pharmacophore pos-
sessing wide range of biological activities. Several substituted tet-
razoles have been shown to possess anticonvulsant [27],
antibacterial [28,29], anti-inﬂammatory [30,31], antinociceptive
[32,33], anticancer [34,35], cyclo-oxygenase inhibition [36] and
hypoglycemic activities [37]. It has also been reported that the
lipophilic nature of tetrazole moiety in a drug improves its oral
bioavailability and cell penetration [38]. One of the marketed
analgesic compound, Alfentanil i contains a tetrazolone moiety and
on the other hand TAK-456 ii with tetrazole ring has a broad-
spectrum antifungal activity [39] Fig. 1a.
Docking is a method which predicts the orientation of one
macromolecule of protein to the ligand when bound to each other,(a
(b
(c
Fig. 1. (a) Marketed drugs containing tetrazole moiety. (b) C. albicans inhthus forming a stable complex at the atomic level [40]. Actually,
drug discovery program is oriented towards the search for lead
structures and thus virtual screening/molecular docking program
constitute a great tool to ﬁnd hit which further undergoes limited
optimization to identify promising lead molecule. In the present
paper, we have carried out docking of the compounds 6h-q and 7h-
q into the base pairs of DNA and active sites of N-myristoyl trans-
ferase (NMT) and dihydrofolate reductase (DHFR). This is because
DNA being speciﬁcally taken as a molecular target for many of the
clinically available drugs which is trending in cancer therapeutics
and is a non-speciﬁc target of cytotoxic agents. It was noticed that
smaller drugmolecules which contain planar polyaromatic systems
bind to double stranded DNA and exhibit more than one binding
mode ie., the intercalation and covalent binding. It has been oriental
as a target for many antitumor as well as antibiotic drugs and hence
further interaction of drug and DNA is important to study the
rational designing of selective targets in pharmacology [41,42].
NMT is a cytosolic monomeric enzyme that catalyzes the transfer of)
)
)
ibiting Quinazolines. (c) Anticancer and antifungal azole quinolines.
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of a number of eukaryotic cellular and viral proteins [43,44].
Although A. fumigatus possess an active NMT enzyme, genetic
studies have shown that NMT gene is essential for the growth and
viability of important pathogenic fungi including C. albicans [45].
Hence, NMT is an important and promising target enzyme in the
design and development of novel antifungal agents. By earlier re-
ports, NMT has also been known to be a promising target of anti-
cancer agents and also a large number of potent NMT inhibitors
showing antifungal, antiparasitic activities have been reported [46].
DHFR catalyzes the reduction of dihydrofolic acid to tetrahy-
drofolic acid viz., involved in the biosynthesis of DNA. Therefore,
inhibition of DHFR causes the cessation of DNA synthesis which
ultimately leads to cell death. This enzyme is target of intervention
for a number of well-known drugs viz., the antibacterial agent
Trimethoprim and the anticancer agent Methotrexate [47]. Inter-
estingly, DHFR inhibitors have also shown in vitro antifungal ac-
tivity. For example, pyrrolo-2,4-diaminoquinazolines iii and iv have
shown potent activity against C. albicans Fig. 1b [48,49].
Thus, the fusion of quinoline to the tetrazole ring is speculated
to increase the biological activity. This prompted us to design and
construct a system containing tetrazole ring with the quinoline
matrix to serve as a new scaffold for the synthesis of anticancer
agents v-vi [50,51] and antifungals vii-viii represented in Fig. 1c
[52,53].
The designed compounds consist of a quinoline nucleus which
serves as pharmacophore and the non-heterocyclic part viz., phenyl
group separated by a tetrazole bridge represents the linker as
shown in Fig. 2. Due to the planarity, there is more hydrogen bond
environment with tetrazolates as indicated by computational data
[54]. The pKa value of tetrazole is more than carboxylic surrogates
which makes it a lipophilic part for oral bioavailability and
improved duration of action. Substituents at the 6th position on the
core moiety i.e., quinoline rationally increases the activity of the
scaffold as awhole [55]. All these observations lead us to design the
molecules as shown in Fig. 2.
These observations have also been substantiated by molecular
docking with DNA and into the active sites of NMT (A. fumigatus)
and DHFR (C. albicans) as targets. The docking studies have beenFig. 2. SAR based designfurther corroborated by in vitro analyses.2. Results and discussion
2.1. Pharmacology
2.1.1. DNA docking simulation
Docking studies were carried out on Surﬂex-Dock program
which is a surface-basedmolecular similarity wherein ligands were
docked into the protein to optimize the value of the scoring func-
tion. Since DNA is the target for many of the drugs used in cancer
therapeutics, the study was performed on both PDB 1AU5 and PDB
453D to support the interaction and preferred binding mode of
compounds 6h-q and 7h-qwith DNA. The protein crystal structures
were obtained from the PDB (www.rcsb.org/pdb).
The docking study on PDB 1AU5 revealed that compounds 6h
and 6i act as covalent cross linkers, as they showed covalent cross-
linking mode of binding with the base pairs of DNA helix structure
PDB 1AU5. As depicted in Fig. 3(a), compound 6h showed covalent
cross-linkage mode of binding with the base pair of DNA helix,
while the nitrogen of tetrazole ring forms a weak hydrogen bond
with hydrogen of DC12 base pair. Also in Fig. 3 (b), the compound 6i
showed the same mode of binding as that of compound 6h, makes
four hydrogen bonding interaction. Two nitrogen of tetrazole ring
makes three hydrogen bonds, onewith DA11 base pair, twowith DC
12 base pairs and another one is from the oxygen atom of the
methoxy group at 6th position of the quinoline ring with hydrogen
of DA14 base pair. On the other hand, the docking study on PDB
453D revealed that compounds 6h and 6i act as intercalator (See
Fig. 4).
As depicted in Fig. 5 (a) and (b), they may undergo threading or
classical intercalation. This observation also substantiated the
in vitro anticancer screening wherein, these two compounds
exhibited potent activity. The predicted binding energies of all the
compounds on PDB 1AU5 are listed in Table 1 which shows that the
compound 6h and 6i exhibits the highest C-score values of 4.19 and
3.94 which is in agreement with our observed in vitro results. The
binding energies of titled compounds on PDB 453D are provided
(Table No. S19, Supplementary Information) (see Fig. 6).of title compounds.
Fig. 3. (a) 3D binding model of compound 6h docked into the active pocket of PDB: 1AU5, (b) 3D binding model of compound 6i docked into the active pocket of PDB: 1AU5.
Fig. 4. Binding interactions of 6h and 6i at the active site of PDB 1AU5.
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Fig. 5. (a) Interaction of compound 6h at the binding site of PDB 453D, (b) Interaction of compound 6i at the binding site of PDB 453D.
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The orientation of inhibitor bound in the active sites of both
NMT and DHFR as templates to study antifungal activity against
A. fumigatus and C. albicans respectively was ascertained by docking
study. The protein crystal structure ﬁle (PDB ID: 4CAW; B-Chain and
1AI9) was taken from PDB (www.rcsb.org/pdb). The molecular
docking studies suggested that all the tested compounds show
different binding modes with the active site of one or more amino
acids through hydrogen bonding in the active pocket of the
enzyme. The study revealed that the compounds 6k, 6l, 6p and 7q
show exceptional interaction against NMT and DHFR. As shown in
Fig. 7 (a), compound 6k formed four hydrogen bonds and its C score
and Crash score are 7.14 and 1.58 kcal/mol and is considered to be
a good inhibitor of DHFR (PDB: 1AI9). The nitrogen atom at 5th
position of the tetrazole ring in compound 6kmakes one hydrogen
bonding interaction with amino acid residue ILE96 (N————
H.ILE96; 2.43 Å) and remaining three interactions came from the
nitrogen atom present at 2nd position of tetrazole ring which make
two hydrogen bonding interactions with hydrogen of ARG79 (N—
H.ARG79; 2.14 Å and 2.33 Å) and lastly nitrogen atom of quinoline
ring makes hydrogen bonding interaction with ARG79 (N—
H.ARG79; 2.07 Å).
As the depicted in Fig. 7 (b), compound 7q revealed one
hydrogen bond and its C score and Crash score are 5.76
and 1.31 kcal/mol and is considered to be a good inhibitor of NMT
(PDB ID: 4CAW) to exhibit the activity against A. fumigatus. A ni-
trogen atom of quinoline ring makes hydrogen bonding interaction
with SER378 (N——H.SER378; 2.11 Å). The C-score (Consensus
score) indicated the summary of all the forces interacted betweenthe ligands and enzyme. Crash score revealed that probable pene-
tration into the binding site was in favor of ligands under study.
Charge and van derWaals interactions between the protein and the
ligand suggested that compounds 6k, 6l, 6p and 7q are versatile
compared to other ligands. Scoring of compounds with respect to
the reward for hydrogen bonding, lipophilic contact, and rotational
entropy, along with, intercept terms revealed that compounds 6k,
6l, 6p and 7q showed increased interactions with the protein than
other compounds. The binding energies of titled compounds on
enzyme DHFR (Table No. S20, Supplementary Information) and
NMT (Table No. S21, Supplementary Information) are provided.
2.2. Chemistry
Benzyl/Benzylthio tetrazole 2a-bwas prepared as per Scheme 1.
2-Chloro-6-substituted-quinoline-3-carbaldehyde 3c-g was pre-
pared by Vilsmeier-Haack reactionwhich further was reduced using
NaBH4 to the corresponding alcohol 4c-g. This later gave 3-(bro-
momethyl)-2-chloro-6-substituted quinoline 5c-g when treated
with phosphorous tribromide in DCM. N-Alkylation of 5-
substituted tetrazole 2a-b with 3-(bromomethyl)-2-chloro-6-
substituted quinoline 5c-g in presence of anhydrous potassium
carbonate led to the formation of regioisomers 3-[(5-benzyl/ben-
zylthio-2H-tetrazol-2-yl) methyl]-2-chloro-6-substituted quino-
line 6h-q and 3-[(5-benzyl/benzylthio-1H-tetrazol-1-yl) methyl]-
2-chloro-6-substituted quinoline 7h-q in almost 1:1 ratio at room
temperature at 76e92% yields Scheme 2. Also, literature reports
revealed that, 5-substituted tetrazole forms 1H and 2H-tautomers
Fig. 8.
Table 1
Surﬂex docking scores (kcal/mol) of the titled compounds 6h-q and 7h-q on PDB 1AU5.
Compound C Scorea Crash Scoreb Polar Scorec D Scored PMF Scoree G Scoref Chem Scoreg
6h* 4.19 1.01 2.07 133.78 83.57 172.04 18.18
6i* 3.94 0.99 0.87 135.80 77.78 192.66 15.80
6j 3.56 0.52 1.10 115.40 69.77 146.53 11.38
6k 3.30 0.73 1.31 125.46 41.12 153.76 12.53
6l 3.88 0.86 2.12 127.79 85.31 149.54 17.50
6m 2.61 0.75 0.21 121.94 68.45 160.62 10.85
6n 3.23 0.70 0.80 137.84 86.13 164.12 14.94
6o 3.65 0.82 0.10 131.18 44.86 161.71 12.23
6p 2.95 0.75 0.01 121.94 68.45 160.62 10.85
6q 3.10 0.89 0.71 134.95 98.31 172.21 12.43
7h 3.84 0.59 0.20 122.35 69.11 168.63 11.83
7i 2.92 0.49 2.17 123.67 82.88 149.67 17.66
7j 2.81 0.76 0.82 123.87 70.37 158.72 10.93
7k 2.79 0.80 1.00 132.95 64.77 178.45 12.24
7l 2.48 0.53 0.81 107.17 65.85 131.46 11.92
7m 2.24 0.61 0.43 134.04 67.68 172.32 11.01
7n 2.97 0.78 0.34 123.24 55.74 152.43 12.50
7o 2.84 0.37 0.62 137.59 51.74 171.33 13.66
7p 3.24 0.52 0.01 129.99 58.74 147.65 13.88
7q 3.70 0.62 0.04 120.59 65.59 157.49 10.93
*Asterisk indicates the compound with highest C Score.
a C-Score (Consensus Score) integrates a number of popular scoring functions for ranking the afﬁnity of ligands bound to the active site of a receptor and reports the output
of total score.
b Crash-score revealed the inappropriate penetration into the binding site. Crash scores close to 0 are favorable. Negative numbers indicate penetration.
c Polar is indicating the contribution of the polar interactions to the total score. The polar score may be useful for excluding docking results that make no hydrogen bonds.
d D-score for charge and van der Waals interactions between the protein and the ligand.
e PMF-score indicating the Helmholtz free energies of interactions for protein-ligand atom pairs (Potential of Mean Force, PMF).
f G-score showing hydrogen bonding, complex (ligand-protein), and internal (ligand-ligand) energies.
g Chem-score points for H-bonding, lipophilic contact, and rotational entropy, along with an intercept term.
Fig. 6. Binding interactions of 6k into the active site of the enzyme DHFR and 7q into the active site enzyme NMT.
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attempted Buchwald-Hartwig coupling reaction [56]. For this, pre-
cursor 8a-b was prepared by [3 þ 2] cycloaddition of nitriles with
tributyltin azide. The azide was generated in situ from tributyltin
chloride and sodium azide, and the palladium-based coupling of
8a-bwas attempted with 3-(bromomethyl)-2-chloro-6-substituted
quinoline 5c-g as a substrate in presence of base (anhydrous K2CO3)
in dry THF under N2 atmosphere for 24 h Scheme 3. However, on
monitoring the reaction we found, instead of formation of com-
pound 6h-q as the sole product, there was formation of both the
regioisomers. This was because base such as potassium carbonate
removed the acidic proton of tetrazole and formed anion as shown
in Scheme 4. This led to the formation of both the isomers due to
failure in the completion of coupling cycle. This in turn resulted in
failure of regioselectivity during the reaction process.
The regioisomers 6h-q and 7h-qwere analyzed by LC-MSwhich
indicates that the two isomers are in almost equal proportions.
Later, the regioisomers were eluted in the ratio 1:1. The structures
of these compounds were conﬁrmed by 1H, 13C NMR, mass spectra,X-ray crystallography and elemental analyses. A medium intense
band appeared in all the compounds around 1589-1625 cm1
correspond to the C]N stretching. In case of 1H NMR, the C4-H of
the quinoline ring appeared as a singlet around 8.08e8.59 ppm. In
case of 2,5-regioisomer, the N-CH2 protons ﬂanked between quin-
oline and tetrazolyl ring resonate as a singlet around
6.15e6.10 ppm. Similarly, in case of 1,5-regioisomer these N-CH2
protons resonate at 5.76e6.11 ppm. The C-CH2-C protons resonate
as a singlet at 4.08e4.36 ppm in case of 2,5-regioiosmer and at
4.19e4.55 ppm for 1,5-regioisomer. The signals appeared around
7.03e7.48 ppm was attributed to the aromatic protons in all the
compounds. In case of 13C NMR spectral analyses, the C5 carbon of
tetrazolyl ring resonated around 165-154 ppm and the other
magnetically non equivalent carbon atoms appeared as signals at
their respective chemical shift values. The mass spectral analyses of
all the title compounds have shown the molecular ion peak cor-
responding to their molecular mass.
Fig. 7. (a) 3D binding model of compound 6k docked into the active pocket of the enzyme DHFR, (b) 3D binding model of compound 7q docked into the active pocket of the enzyme
NMT.
Scheme 1. Synthesis of compounds 2a-b.
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The geometry of 2,5 and 1,5-regioisomers was studied by X-raycrystallographic studies. Molecular structure, numbering of atoms
and the crystal packing of compound 6i is depicted in Fig. 9. This
compound crystallizes in a triclinic system with the P-1 space
group and an asymmetric unit contains just one molecule. The
lattice parameters a¼ 7.100 (4) Å, b¼ 10.339 (6) Å, c¼ 11.692 (7) Å,
a ¼ 66.611 (14) , b ¼ 77.985 (14) , g ¼ 87.056 (16) . The dihedral
angle between quinoline rings with the tetrazole and benzene rings
of the molecules are 77.53 (11)  and 85.39 (12) respectively. In the
structure, all bond lengths and angles are within normal ranges
[57]. The crystal structure is stabilized by weak intermolecular C—
H/N and C—H/O hydrogen bonds. The crystal packing is further
stabilized by p—p and C—H… p interactions. The CIF ﬁle has been
deposited with CCDC No. 1482262.
Scheme 2. Synthesis of title compounds 6h-q and 7h-q.
Fig. 8. 1H and 2H-Tautomers of 5-substituted tetrazoles.
Scheme 3. Attempted synthetic route to get regioselec
Scheme 4. Tautomerism in 5
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packing of compound 7h is represented in Fig. 10. The compound
7h crystallizes in a triclinic systemwith the P-1 space group and an
asymmetric unit contains two crystallographically equivalent
molecules. The lattice parameters are a ¼ 8.6210 (2) Å, b ¼ 12.4132
(3) Å, c ¼ 16.1259 (4) Å, a ¼ 74.2420 (10) , b ¼ 86.187 (2) ,
g ¼ 81.483 (2) . The dihedral angle between quinoline rings with
the tetrazole and benzene rings of the molecules are 79.54 (8)  &
3.13 (12) for onemolecule and 74.22 (11)  & 48.20 (11) respectively.
In the structure, all bond lengths and angles are within normal
ranges. The crystal structure is stabilized by other intermolecular
C—H/N hydrogen bonds. In the crystal, inversion related CeH/N
interactions generate an R22 (8) ring pattern. The crystal packingtive product 6h-q by Buchwald Hartwig reaction.
-substituted tetrazoles.
Fig. 9. (a) The ORTEP structure of compound 6i (Displacement ellipsoids are drawn at the 50% probability level), (b) Packing diagram of compound 6i, (c) Planes of the compound 6i.
Fig. 10. (a) The ORTEP structure of compound 7h (Displacement ellipsoids are drawn at the 50% probability level), (b) Packing diagram of compound 7h, (c) Planes of the compound
7h.
S.K.J. Shaikh et al. / European Journal of Medicinal Chemistry 128 (2017) 258e273266further stabilized by p—p and C—H… p interaction. The CIF ﬁle has
also been deposited with CCDC No. 1482510.2.4. Anticancer activity
The newly synthesized compounds were also subjected to
in vitro anticancer screening in a single high dose (105 M) con-
centration against full 60 human cancer cell lines at the National
Cancer Institute (NCI), USA under DTP drug therapeutics program.
The output from the single dose screen is reported as a graph of
mean growth percent of the treated cells and is available for anal-
ysis by the COMPARE program [58]. This allows detecting both
growth inhibition values (between 0 and 100) and cytotoxicity
values (less than 0). All the synthesized compounds 6h-q and 7h-q
have been registered and 14 of them were selected for anticancer
activity. The compounds 6h (NSC: D-785704/1), 6i (NSC: D-785706/
1), 6k (NSC: D-785708/1), 6l (NSC: D-785710/1), 6m (NSC: D-787573/1), 6o (NSC: D-787575/1), 6q (NSC: D-787577/1), 7h (NSC:
D-785705/1), 7i (NSC: D-785707/1), 7k (NSC: D-785709/1), 7l (NSC:
D-785711/1), 7m (NSC: D-787574/1), 7o (NSC: D-787576/1), 7q
(NSC: D-787578/1) have been screened for single high dose
(105 M) concentration on all the 60 human cancer cell lines
methodized into nine sub-panels derived from nine different hu-
man cancer types: leukemia, non-small cell lung, cancer, colon,
CNS, melanoma, ovarian, renal, prostate and breast cancer cell lines.
Following are the percentage growth inhibition (GI %) of the
treated cells at 105 M concentration of the compound 6h (2,5-
isomer without substitution, Table 2): Melanoma SK-MEL-5 (GI %
99.28), Ovarian Cancer OVCAR-4 (GI % 70.32), Breast Cancer MDA-
MB-468 (GI % 88.92) and cytotoxicity effect against Renal Cancer
UO-31 cell line. Compound 6i (2,5-isomer with methoxy substitu-
tion, Table 2): Leukemia MOLT-4 (GI % 89.65), Non-Small Cell Lung
Cancer EKVX (GI % 75.51), Colon Cancer COLO 205 (GI % 75.09), CNS
Cancer SF-295 (GI % 62.61), Melanoma UACC-257 (GI % 73.55),
Table 2
Growth inhibition (GI %) in single dose assay (105M) concentration for compound
6h (NSC: D-785704/1) and 6i (NSC: D-785706/1).
Panel/Cell line 6h
Growth Inhibition (GI %)
6i
Growth Inhibition (GI %)
Leukemia
HL-60(TB) 12.11 43.42
K-562 44.81 67.10
MOLT-4 56.88 89.65
SR 63.02 77.09
Non-Small Cell Lung Cancer
A549/ATCC 46.10 68.50
EKVX 63.86 75.51
NCI-H226 41.76 61.00
NCI-H23 54.45 67.46
NCI-H460 25.68 60.05
NCI-H522 57.89 61.95
Colon Cancer
COLO 205 17.26 75.09
HCC-2998 18.68 40.99
HCT-116 64.93 70.81
HCT-15 35.00 63.53
HT29 28.45 72.60
KM12 33.68 63.52
SW-620 13.42 33.59
CNS Cancer
SF-268 34.29 48.51
SF-295 52.44 62.61
SF-539 18.8 32.50
SNB-19 10.15 42.04
SNB-75 44.64 42.90
U251 23.74 46.77
Melanoma
LOX IMVI 46.42 57.12
MALME-3M 34.40 65.62
M14 26.40 69.70
MDA-MB-435 34.69 70.71
SK-MEL-2 41.24 50.41
SK-MEL-28 15.32 52.55
SK-MEL-5 99.28 147.15(Cytotoxic)
UACC-257 46.37 73.55
UACC-62 48.28 64.87
Ovarian Cancer
IGROV1 49.09 56.76
OVCAR-3 40.46 50.15
OVCAR-4 70.32 80.26
OVCAR-5 4.25 17.18
OVCAR-8 28.39 59.53
NCI/ADR-RES 47.87 79.89
SK-OV-3 42.58 50.64
Renal Cancer
786e0 27.12 52.54
ACHN 47.82 58.53
CAKI-1 59.51 56.07
RXF 393 16.07 39.83
SN12C 29.69 42.70
TK-10 39.08 65.07
UO-31 181.01(Cytotoxic) 85.26
Prostate Cancer
DU-145 24.83 38.39
Breast Cancer
MCF7 54.24 72.06
MDA-MB-231/ATCC 46.95 49.28
HS 578T 23.40 31.08
BT-549 61.06 79.66
T-47D 73.93 97.56
MDA-MB-468 88.92 70.08
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85.26), Prostate Cancer DU-145 (GI % 38.39), Breast Cancer T-47D
(GI % 97.56) and has shown cytotoxicity effect against Melanoma
SK-MEL-5 cell line. Rest of the compounds (6k-m, 6o, 6q and 7h-
7q) showed moderate GI% against all the cell lines.2.5. Antifungal activity
Considering the interactions and binding modes of synthesized
compounds with NMT and DHFR by docking studies, the in vitro
antifungal activity was evaluated. The antifungal activity of syn-
thesized compounds was tested against A. fumigatus and C. albicans
strains using Fluconazole as reference by the Disc Diffusion
method. The Zone of Inhibition (ZOI) and Minimum Inhibitory
Concentrations (MIC) are summarized in Table 3. Antifungal ac-
tivity with MIC 50 mg/ml was observed in all the derivatives.
Drastic change was observed when compared with the
regioisomers of the same derivative showing the afﬁnity of mole-
cule towards fungal strains. The derivatives having halo-
substituents showed good activity when compared with other
derivatives. Compounds 6k, 6l, 6p, 7k, 7l, 7p showed good activity
at minimal concentrations, whereas compounds 6q and 7q (the
2,5- and 1,5-isomer with ﬂuoro substituent at the 6th position)
showed an excellent activity against A. fumigatus compared to
C. albicans, at a low MIC value of 2.5 mg/ml. All other compounds
showedmoderate to good activity when compared to the standard.
Generally it was observed that halogens such as F and Br at the
6th position contributed to the in vitro results in case of antifungal
activity, whereas H,OCH3, CH3 has less effects. Especially, ﬂuorine at
the 6th position is responsible for the increase in in vitro activity
[59]. The increase in activity with respect to the substituents fol-
lows the sequence as, F > Br > OCH3CH3>H. In case of in vitro
anticancer activity, we observed the change in order of sequence of
activity as OCH3>H > CH3>Br > F. The signiﬁcance of spatial de-
terminators contributes little to the activity when attached to the
acidic part, but when the length increases, it leads to substantial
decrease in the activity [60]. Interestingly, in vitro antifungal ac-
tivity revealed that the 1,5-regiosomer has shown more inhibition
compared to 2,5-regioisomer indicating the regioselectivity of an
enzyme.
3. Conclusions
A library of 2,5- and 1,5-regioisomers viz., 3-[(5-benzyl/benzyl
thio-2H-tetrazol-2-yl) methyl]-2-chloro-6-substituted quinoline
6h-q and 3-[(5-benzyl/benzyl thio-1H-tetrazol-1-yl) methyl]-2-
chloro-6-substituted quinoline 7h-q respectively have been syn-
thesized and thoroughly characterized. Docking methods revealed
that compounds 6h and 6i are covalent cross linker and an inter-
calator on the DNA helix structure of the protein structure owing to
the in vitro results. Amongst 20 compounds, 14 compounds were
screened at a single high dose (105 M) concentration. Out of these,
compounds 6h and 6i have shown 40e99% growth inhibition of the
tumor cells against various cell lines at 105 M concentration.
Compounds 6h and 6iwere also cytotoxic against Renal Cancer UO-
31 andMelanoma SK-MEL-5 cell lines respectively. Docking into the
active pocket of NMT and DHFR revealed that compounds (with
bromo and ﬂuoro substituents) 6k, 6l, 6p and 7q exhibited good
binding mode into the amino acids, which are compatible with
their in vitro screening results. Antifungal activity against
A. fumigatus and C. albicans, showed inhibition at a minimal con-
centration of around (25e2.5) mg/ml. This revealed that compounds
6k and 7q are better inhibitors of DHFR and NMT respectively,
hence showed excellent inhibition of fungal strains at minimal
concentrations. It was interesting to note that, compounds 6h and
6i with good anticancer activity rather showed poor inhibition for
fungal strain under investigation and the compounds 6k and 7q
with potent antifungal property did not exhibit promising anti-
cancer activity. These scaffolds with potent pharmacological
property may be considered to be lead compounds for the devel-
opment of potent anticancer and antifungal agents.
Table 3
In vitro antifungal activities of 6h-q and 7h-q expressed in ZOI (mm) and MIC (mg/ml).
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4.1. General
All AR grade common reagents and solvents were obtained from
Sigma Aldrich, SD ﬁne chemicals and Alfa Aesar and used without
further puriﬁcation. Thin layer chromatography (TLC) was per-
formed on Merck Silica Gel 60 F254 and visualized under UV light
chamber. Melting points were determined in open capillary tubes
and are uncorrected. Column chromatography was carried out us-
ing silica gel (Silica Gel 60e120 mesh, 120e250 mm). 1H (400 MHz)
and 13C (100 MHz) NMR spectra were recorded on Bruker AV-400
and JEOL JNM-ECX500II spectrometer respectively using DMSO-
d6. Chemical shifts (d) were reported as parts per million (ppm)
relative to tetramethylsilane (TMS) as an internal standard. Mass
spectra were recorded using a Finnegan MAT (Model MAT 8200)
spectrometer. Elemental analyses for C, H and N were performed
using a Heraeus CHN rapid analyzer. Single Crystal X-ray analyses
were carried out using Bruker SMART CCD area-detector diffrac-
tometer with monochromatic Mo Ka radiation at room tempera-
ture. The crystalline state of a crystal is characterized by a long
range, well deﬁned three dimensional orders.4.2. Synthetic procedures and spectral data
4.2.1. General procedure for the synthesis of 5-(benzyl/benzylthio)-
2H-tetrazole (2a-b)
Amixture of benzyl cyanide (0.003 mol), NaN3 (0.0134 mol) and
triethylamine hydrochloride (TEA.HCl) (0.013 mol) in toulene was
heated to 110e115 C for 48 h with stirring. The reaction mixture
was cooled to room temperature and stirred for 30 min at RT. The
product was extracted with water (15 ml) and NaOH solution (5%,
2 ml). To the aqueous layer which is basic in condition, dilutehydrochloric acid was added drop wise to get tetrazole product.
After ﬁltration the product was dried under reduced pressure to get
a crude product which was recyrstallised from acetone to get the
compound 2a-b.
4.2.2. General procedure for the synthesis of 2-chloroquinolin-3-
carbaldehyde (3c-g)
Vilsmeir-Haack adduct was prepared by adding phosphorous
oxychloride (0.35 mol) drop wise to the cold solution of DMF
(0.125 mol) with constant stirring. To this adduct, substituted
acetanilide (0.05 mol) was added slowly and stirred well for
15e20 min. The mixture was then reﬂuxed for 16 h at 70e80 C.
After completion of the reaction, the contents were then poured
into ice water and stirred for 30 min. The 2-chloroquinoline-3-
carbaldehyde 3c-g was precipitated which was ﬁltered and
washed well with water. Dried and recrystallised from ethyl
acetate.
4.2.3. General procedure for the synthesis of (2-chloroquinolin-3-
yl) methanol (4c-g)
To the well stirred mixture of 2-chloroquinoline-3-
carbaldehyde 3c-g (0.01 mol) in methanol (10 ml), NaBH4
(0.01mol) was added in small portions, and themixturewas stirred
at room temperature for 15e20min. The completion of the reaction
was monitored by TLC and the reaction mixture was concentrated
under vacuum. The mixture was poured into ice cold water and the
(2-chloroquinolin-3-yl) methanol 4c-g separated as solid was
ﬁltered off and recrystallised from ethyl acetate.
4.2.4. Synthesis of 3-(bromomethyl)-2-chloro-6-substituted
quinoline (5c-g)
(2-Chloroquinolin-3-yl) methanol (0.01 mol) was dissolved in
DCM (10e15 ml) at 5 C and stirred well. After 10e15 min, PBr3
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1 h. After completion of the reaction, DCM was removed under
vacuum and the mixture was poured into ice and neutralized by
adding a saturated solution of NaHCO3. The precipitate was ﬁltered
and dried.
4.2.5. General procedure for the synthesis of 5-(benzyl/benzylthio)-
2-(tributylstannyl)-2H-tetrazole (8a-b)
Tributyltin chloride (2.5 mol) and NaN3 (2.5 mol) were charged
into a solution of appropriate nitrile (1.0 mol) taken in o-xylene
(20 ml). The reaction mixture was stirred at reﬂux for stipulated
time of 15 h. After completion of the reaction, the solvent was
evaporated to get the oily compound 8a-b.
4.2.6. Preparation of 3-[(5-benzy/benzylthio-2H-tetrazol-2-yl)
methyl]-2-chloro-6-substituted quinoline (6h-q) and 3-[(5-benzyl/
benzylthio-1H-tetrazol-1-yl)methyl]-2-chloro-6-substituted
quinoline (7h-q)
Mixture of 5-(benzyl/benzylthio)-2H-tetrazole (2a-b) (0.01mol)
and 3-(bromomethyl)-2-chloro-6-substituted quinoline (5c-g)
(0.01mol) and anhydrous potassium carbonate (0.02 mol) in dry
acetone was stirred at room temperature until the completion of
reaction by TLC, hexane: ethyl acetate (7:3). The reaction mixture
was ﬁltered, washed with acetone and the ﬁltrate was evaporated
to dryness to get regioisomers which were further separated by
column chromatography using hexane: ethyl acetate (30%) as an
eluent.
4.2.6.1. 3-[(5-Benzyl-2H-tetrazol-2-yl)methyl]-2-chloroquinoline 6h.
White solid; Yield: 85%; m.p. 94e96 C; IR (KBr, cm1): 3034 (C-H),
1619 (C]N), 1591 (C]C). 1H NMR (400 MHz, DMSO-d6, d ppm):
8.05 (1H, d, J78 ¼ 8.8 Hz, “H800 ArH), 7.97 (1H, d, J48 ¼ 0.8 Hz, “H400
ArH), 7.86 (1H, d, J56 ¼ 8.4 Hz, “H500 ArH), 7.71 (1H, dd, J67 ¼ 7.2 Hz
and J78 ¼ 8.4 Hz, “H700 ArH), 7.69 (1H, dd, J67 ¼ 7.6 Hz and
J65 ¼ 8.4 Hz, “H600 ArH), 7.19e7.30 (5H, m, ArH), 6.13 (2H, s, N-CH2),
4.22 (2H, s, CH2 of benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm):
165.22, 149.32, 146.74, 140.97, 136.86, 131.60, 128.56, 128.25, 127.95,
127.85, 127.62, 127.46, 126.63, 126.58, 53.74, 30.73. Calcd Mass
335.79 MS (m/z): 337.09 (Mþ2), 335.09 (Mþ). Anal. Calcd for
C18H14N5Cl: C, 64.38; H, 4.20; N, 20.86. Found: C, 64.49; H, 4.28; N,
20.89.
4.2.6.2. 3-[(5-Benzyl-2H-tetrazol-2-yl)methyl]-2-chloro-6-
methoxyquinoline 6i. White solid; Yield: 91%; m.p. 96e98 C; IR
(KBr, cm1): 3056 (C-H), 1619 (C]N), 1595 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.36 (1H, d, J78 ¼ 8.6 Hz, “H800 ArH),
7.87 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.50 (1H, d, J57 ¼ 1.6 Hz,
“H500ArH), 7.47 (1H, dd, J57 ¼ 1.6 Hz and J78 ¼ 8.6 Hz, “H700 ArH),
7.19e7.30 (5H, m, ArH), 6.11 (2H, s, N-CH2), 4.22 (2H, s, CH2 of
benzyl), 3.89 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
165.84, 158.67, 147.03, 143.25, 140.05, 137.48, 129.63, 129.19, 129.07,
128.59, 127.21, 126.43, 124.48, 106.59, 56.28, 54.31, 31.37. Calcd
Mass 365.82 MS (m/z): 367.10 (Mþ2), 365.10 (Mþ). Anal. Calcd for
C19H16N5OCl: C, 62.38; H, 4.41; N, 19.14. Found: C, 62.43; H, 4.43; N,
19.10.
4.2.6.3. 3-[(5-Benzyl-2H-tetrazol-2-yl)methyl]-2-chloro-6-
methylquinoline 6j. Off White solid; Yield: 89%; m.p. 78e80 C; IR
(KBr, cm1): 3061 (C-H), 1617 (C]N), 1565 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.38 (1H, d, J78 ¼ 8.8 Hz, “H800 ArH),
7.84 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.50 (1H, d, J57 ¼ 1.6 Hz,
“H500ArH), 7.49 (1H, dd, J57 ¼ 1.6 Hz and J78 ¼ 8.8 Hz, “H700 ArH),
7.11e7.32 (5H, m, ArH), 6.13 (2H, s, N-CH2), 4.22 (2H, s, CH2 of
benzyl), 2.32 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
165.78, 159.11, 147.32, 136.43, 136.39, 135.60, 131.56, 129.78, 129.58,129.13, 129.04, 128.64, 127.42, 126.58, 125.34, 54.6, 31.33, 23.67.
Calcd Mass 349.82 MS (m/z): 351.11 (Mþ2), 349.11 (Mþ). Anal. Calcd
for C19H16N5Cl: C, 65.24; H, 4.61; N, 20.02. Found: C, 65.20; H, 4.58;
N, 20.11.
4.2.6.4. 3-[(5-Benzyl-2H-tetrazol-2-yl)methyl]-6-bromo-2-
chloroquinoline 6k. Pale yellow solid; Yield: 85%; m.p. 104e106 C;
IR (KBr, cm1): 3067 (C-H), 1595 (C]N), 1556 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.42 (1H, d, J78 ¼ 8.6 Hz, “H800 ArH),
7.97 (1H, d, J48 ¼ 1.2 Hz, “H400 ArH), 7.85 (1H, d, J57 ¼ 1.4 Hz, “H500
ArH), 7.61 (1H, dd, J57¼ 1.4 Hz and J78¼ 8.4 Hz, “H700 ArH), 7.10e7.31
(5H, m, ArH), 6.10 (2H, s, N-CH2), 4.21 (2H, s, CH2 of benzyl). 13C
NMR (100 MHz, DMSO-d6, d ppm): 165.32, 149.66, 147.62, 136.52,
136.24, 133.32, 131.48, 130.7, 129.69, 129.51, 128.87, 128.45, 127.89,
118.78, 56.43, 31.43. Calcd Mass 414.69 MS (m/z): 417.12 (Mþ4),
415.11 (Mþ2), 413.10 (Mþ). Anal. Calcd for C18H13N5BrCl: C, 52.13; H,
3.16; N, 16.89. Found: C, 52.10; H, 3.13; N, 16.85.
4.2.6.5. 3-[(5-Benzyl-2H-tetrazol-2-yl)methyl]-2-chloro-6-
ﬂuoroquinoline 6l. Pale yellow solid; Yield: 87%; m.p. 80e82 C; IR
(KBr, cm1): 3058 (C-H), 1596 (C]N), 1567 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.51 (1H, d, J78 ¼ 8.4 Hz, “H800 ArH),
8.45 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.92 (1H, d, J57 ¼ 1.4 Hz, “H500
ArH), 7.79 (1H, dd, J57¼ 1.4 Hz and J78¼ 8.6 Hz, “H700 ArH), 7.19e7.28
(5H, m, ArH), 6.14 (2H, s, N-CH2), 4.22 (2H, s, CH2 of benzyl). 13C
NMR (100 MHz, DMSO-d6, d ppm): 165.39, 158.34, 154.65, 140.25,
139.74, 136.84,136.33, 130.68,130.60,128.59,128.45,126.60,121.73,
111.72, 55.34, 30.73. Calcd Mass 353.78 MS (m/z): 355.08 (Mþ2),
353.08(Mþ). Anal. Calcd for C18H13N5FCl: C, 61.11; H, 3.70; N, 19.80.
Found: C, 61.13; H, 3.68; N, 19.82.
4.2 .6 .6 . 3- [ (5- (Benzyl th io)-2H-tetrazol-2-yl )methyl ] -2-
chloroquinoline 6m. White solid; Yield: 82%; m.p. 102e104 C; IR
(KBr, cm1): 3067 (C-H), 1615 (C]N), 1594 (C]C), 690 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.59 (1H, d, J78 ¼ 8.6 Hz, “H800
ArH), 8.54 (1H, d, J48 ¼ 1.6 Hz, “H400 ArH), 8.09 (1H, d, J56 ¼ 8.2 Hz,
“H500 ArH), 7.99 (1H, dd, J67¼ 6.8 Hz and J78¼ 8.6 Hz, “H700 ArH), 7.86
(1H, dd, J67 ¼ 6.8 Hz and J65 ¼ 8.4 Hz, “H600 ArH), 7.15e7.73 (5H, m,
ArH), 6.11 (2H, s, N-CH2), 4.36 (2H, s, CH2 of benzyl). 13C NMR
(100 MHz, DMSO-d6, d ppm): 162.86, 149.38, 147.45, 142.63, 141.30,
136.99, 131.76, 128.86, 128.39, 128.27, 127.93, 127.70, 127.65, 127.34,
55.97, 34.13. Calcd Mass 369.87 MS (m/z): 371.08 (Mþ2),
369.08(Mþ). Anal. Calcd for C18H14N5SCl: C, 57.71; H, 3.42; N, 19.79.
Found: C, 57.69; H, 3.45; N, 19.81.
4.2.6.7. 3-[(5-(Benzylthio)-2H-tetrazol-2-yl)methyl]-2-chloro-6-
methoxyquinoline 6n. White solid; Yield: 78%; m.p. 96e98 C; IR
(KBr, cm1): 3064 (C-H), 1618 (C]N), 1599 (C]C), 710 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.36 (1H, d, J78 ¼ 8.8 Hz, “H800
ArH), 7.87 (1H, d, J48 ¼ 1.2 Hz, “H400 ArH), 7.49 (1H, d, J57 ¼ 1.4 Hz,
“H500 ArH), 7.47 (1H, dd, J57 ¼ 1.4 Hz and J78 ¼ 8.8 Hz, “H700 ArH),
7.14e7.65 (5H, m, ArH), 6.12 (2H, s, N-CH2), 4.32 (2H, s, CH2 of
benzyl), 3.88 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
165.78, 158.61, 146.88, 143.20, 139.64, 137.48, 129.59, 129.10, 129.01,
128.33,127.21,126.21,124.56,105.51, 57.45, 54.28, 34.32. CalcdMass
397.88 MS (m/z): 399.07 (Mþ2), 397.08(Mþ). Anal. Calcd for
C19H16N5OSCl: C, 56.32; H, 3.68; N, 18.24. Found: C, 56.30; H, 3.61;
N, 18.21.
4.2.6.8. 3-[(5-(Benzylthio)-2H-tetrazol-2-yl)methyl]-2-chloro-6-
methylquinoline 6o. Off white solid; Yield: 84%;m.p.106e108 C; IR
(KBr, cm1): 3054 (C-H), 1598 (C]N), 1575 (C]C), 708 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.39 (1H, d, J78 ¼ 8.6 Hz, “H800
ArH), 7.85 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.49 (1H, d, J57 ¼ 1.6 Hz,
“H500 ArH), 7.49 (1H, dd, J57 ¼ 1.59 Hz and J78 ¼ 8.6 Hz, “H700 ArH),
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benzyl), 2.32 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
165.64, 159.16, 147.34, 136.54, 136.21, 135.34, 131.45, 129.76, 129.55,
129.08, 129.03, 128.71, 126.55, 125.41, 54.75, 34.12, 23.58. Calcd
Mass 381.88 MS (m/z): 383.08 (Mþ2), 381.08 (Mþ). Anal. Calcd for
C19H16N5SCl: C, 58.77; H, 3.84; N, 19.04. Found: C, 58.74; H, 3.87; N,
19.02.
4.2.6.9. 3-[(5-(Benzylthio)-2H-tetrazol-2-yl)methyl]-6-bromo-2-
chloroquinoline 6p. Yellow solid; Yield: 80%; m.p. 108e110 C; IR
(KBr, cm1): 3069 (C-H), 1614 (C]N), 1596 (C]C), 717 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.52 (1H, d, J78 ¼ 8.6 Hz, “H800
ArH), 7.95 (1H, d, J48 ¼ 1.2 Hz, “H400 ArH), 7.89 (1H, d, J57 ¼ 1.6 Hz,
“H500 ArH), 7.63 (1H, dd, J57 ¼ 1.6 Hz and J78 ¼ 8.6 Hz, “H700 ArH),
7.14e7.57 (5H, m, ArH), 6.12 (2H, s, N-CH2), 4.11 (2H, s, CH2 of
benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm): 165.29, 149.54,
147.87, 136.48, 136.21, 133.30, 131.42, 130.54, 129.76, 129.48, 128.92,
128.73, 127.76, 117.76, 57.43, 34.13. Calcd Mass 446.75 MS (m/z):
448.97 (Mþ4), 446.97 (Mþ2), 444.98 (M). Anal. Calcd for
C18H13N5SBrCl: C, 47.19; H, 2.56; N,16.18. Found: C, 47.21; H, 2.58; N,
16.20.
4.2.6.10. 3-[(5-(Benzylthio)-2H-tetrazol-2-yl)methyl]-2-chloro-6-
ﬂuoroquinoline 6q. Pale yellow solid; Yield: 88%; m.p. 112e114 C;
IR (KBr, cm1): 3078 (C-H), 1612 (C]N), 1574 (C]C), 721 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.55 (1H, d, J78 ¼ 8.4 Hz, “H800
ArH), 8.38 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.90 (1H, d, J57 ¼ 1.4 Hz,
“H500 ArH), 7.75 (1H, dd, J57 ¼ 1.4 Hz and J78 ¼ 8.4 Hz, “H700 ArH),
7.20e7.68 (5H, m, ArH), 6.152 (2H, s, N-CH2), 4.08 (2H, s, CH2 of
benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm): 165.43, 149.31,
147.81, 140.21, 139.71, 136.78, 136.48, 130.64, 130.43, 128.61, 128.39,
126.54, 121.86, 111.69, 55.48, 34.18. Calcd Mass 385.85 MS (m/z):
387.05 (Mþ2), 385.06 (Mþ). Anal. Calcd for C18H13N5SFCl: C, 54.91;
H, 2.98; N, 18.84. Found: C, 54.89; H, 2.95; N, 18.86.
4.2.6.11. 3-[(5-Benzyl-1H-tetrazol-1-yl)methyl]-2-chloroquinoline
7h. White solid; Yield: 86%, m.p. 120e122 C; IR (KBr, cm1): 3048
(C-H), 1628 (C]N), 1594 (C]C). 1H NMR (400 MHz, DMSO-d6,
d ppm): 8.02 (1H, d, J78¼ 8.8 Hz, “H800 ArH), 7.93 (1H, d, J48¼ 0.8 Hz,
“H400 ArH), 7.84 (1H, d, J56 ¼ 8.4 Hz, “H500 ArH), 7.80 (1H, dd,
J67¼ 7.4 Hz and J78¼ 8.8 Hz, “H700 ArH), 7.64 (1H, dd, J67¼ 7.6 Hz and
J65 ¼ 8.4 Hz, “H600 ArH), 7.05e7.22 (5H, m, ArH), 5.86 (2H, s, N-CH2),
4.45 (2H, s, CH2 of benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm):
153.48, 147.82, 136.76, 136.34, 131.68, 128.88, 128.54, 128.21, 127.98,
127.74, 127.49, 127.11, 126.63, 126.22, 55.34, 28.34. Calcd Mass
335.79 MS (m/z): 337.09 (Mþ2), 335.09(Mþ). Anal. Calcd for
C18H14N5Cl: C, 64.38; H, 4.20; N, 20.86. Found: C, 64.35; H, 4.22; N,
20.84.
4.2.6.12. 3-[(5-Benzyl-1H-tetrazol-1-yl)methyl]-2-chloro-6-
methoxyquinoline 7i. White solid; Yield: 78%, m.p. 156e158 C; IR
(KBr, cm1): 3035 (C-H), 1623 (C]N), 1598 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.21 (1H, d, J78 ¼ 8.6 Hz, “H800 ArH),
7.70 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.44 (1H, d, J57 ¼ 1.6 Hz, “H500
ArH), 7.42 (1H, dd, J57 ¼ 1.6 Hz and J78 ¼ 8.6 Hz, “H700 ArH),
7.06e7.31 (5H, m, ArH), 5.84 (2H, s, N-CH2), 4.44 (2H, s, CH2 of
benzyl), 3.86 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
157.94, 154.83, 145.50, 142.35, 137.18, 134.57, 128.89, 128.74, 128.52,
127.93, 126.88, 126.29, 123.59, 105.98, 55.69, 47.73, 28.17. Calcd
Mass 365.82 MS (m/z): 367.10 (Mþ2), 365.10 (Mþ). Anal. Calcd for
C19H16N5OCl: C, 62.38; H, 4.41; N, 19.14. Found: C, 62.40; H, 4.45; N,
19.16.
4.2.6.13. 3-[(5-Benzyl-1H-tetrazol-1-yl)methyl]-2-chloro-6-
methylquinoline 7j. Off white solid; Yield: 76%, m.p. 128e130 C; IR(KBr, cm1): 3036 (C-H), 1599 (C]N), 1564 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.05 (1H, d, J78 ¼ 8.8 Hz, “H800 ArH),
7.86 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.53 (1H, d, J57 ¼ 1.6 Hz, “H500
ArH), 7.34 (1H, dd, J57 ¼ 1.6 Hz and J78 ¼ 8.8 Hz, “H700 ArH),
7.03e7.33 (5H, m, ArH), 5.76 (2H, s, N-CH2), 4.38 (2H, s, CH2 of
benzyl), 2.30 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
154.72, 149.44, 147.64, 136.89, 136.65, 136.33,131.46, 128.94, 128.72,
127.88, 127.56, 127.45, 127.38, 126.65, 55.48, 28.32, 23.58. Calcd
Mass 349.82 MS (m/z): 351.11 (Mþ2), 349.11 (Mþ). Anal. Calcd for
C19H16N5Cl: C, 65.24; H, 4.61; N, 20.02. Found: C, 65.22; H, 4.64; N,
20.00.
4.2.6.14. 3-[(5-Benzyl-1H-tetrazol-1-yl) methyl]-6-bromo-2-
chloroquinoline 7k. Pale yellow solid; Yield: 82%, m.p.
130e132 C; IR (KBr, cm1): 3062 (C-H), 1613 (C]N), 1591 (C]C).
1H NMR (400 MHz, DMSO-d6, d ppm): 8.47 (1H, d, J78 ¼ 8.59 Hz,
“H800 ArH), 8.20 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.88 (1H, d,
J57 ¼ 1.2 Hz, “H500 ArH), 7.62 (1H, dd, J57 ¼ 1.4 Hz and J78 ¼ 8.4 Hz,
“H700 ArH), 7.11e7.30 (5H, m, ArH), 5.89 (2H, s, N-CH2), 4.19 (2H, s,
CH2 of benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm): 154.77,
149.67, 147.62, 136.91, 136.24, 133.41, 131.48, 129.96, 129.82, 128.97,
128.71, 128.45, 127.89, 118.78, 56.65, 31.38. Calcd Mass 414.69 MS
(m/z): 417.00 (Mþ4), 415.00 (Mþ2), 413.00 (Mþ). Anal. Calcd for
C18H13N5BrCl: C, 52.13; H, 3.16; N, 16.89. Found: C, 52.11; H, 3.10; N,
16.87.
4.2.6.15. 3-[(5-Benzyl-1H-tetrazol-1-yl)methyl]-2-chloro-6-
ﬂuoroquinoline 7l. Pale yellow solid; Yield: 74%, m.p. 100e102 C;
IR (KBr, cm1): 3062 (C-H), 1593 (C]N), 1565 (C]C). 1H NMR
(400 MHz, DMSO-d6, d ppm): 8.80 (1H, d, J78 ¼ 8.6 Hz, “H800 ArH),
8.19 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.82 (1H, d, J57 ¼ 1.4 Hz, “H500
ArH), 7.71 (1H, dd, J57¼ 1.4 Hz and J78¼ 8.6 Hz, “H700 ArH), 7.10e7.37
(5H, m, ArH), 5.82 (2H, s, N-CH2), 4.44 (2H, s, CH2 of benzyl). 13C
NMR (100 MHz, DMSO-d6, d ppm): 161.32, 158.95, 154.81, 144.19,
137.86, 137.26, 130.49, 130.32, 128.84, 128.67, 127.06, 126.78, 121.07,
111.65, 49.44, 28.26. Calcd Mass 353.78 MS (m/z): 355.08 (Mþ2),
353.08 (Mþ). Anal. Calcd for C18H13N5FCl: C, 61.11; H, 3.70; N, 19.80.
Found: C, 61.15; H, 3.67; N, 19.79.
4.2 .6 .16. 3-[(5-(Benzylthio)-1H-tetrazol-1-yl)methyl]-2-
chloroquinoline 7m. White solid; Yield: 79%, m.p. 128e130 C; IR
(KBr, cm1): 3069 (C- H), 1625 (C]N), 1591 (C]C), 717 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.22 (1H, d, J78 ¼ 8.6 Hz, “H800
ArH), 8.00 (1H, d, J48 ¼ 1.6 Hz, “H400 ArH), 7.94 (1H, d, J56 ¼ 8.2 Hz,
“H500 ArH), 7.82 (1H, dd, J67¼6.8 Hz and J78¼ 8.6 Hz, “H700 ArH), 7.66
(1H, dd, J67 ¼ 6.8 Hz and J65 ¼ 8.4 Hz, “H600 ArH), 7.18e7.33 (5H, m,
ArH), 5.66 (2H, s, N-CH2), 4.52 (2H, s, CH2 of benzyl). 13C NMR
(100 MHz, DMSO-d6, d ppm): 153.80, 148.83, 147.28, 139.61, 136.41,
131.61, 128.97, 128.94, 128.48, 128.34, 127.98, 127.88, 127.72, 127.58,
50.07, 36.88. Calcd Mass 367.86 MS (m/z): 369.06 (Mþ2), 367.07
(Mþ). Anal. Calcd for C18H14N5SCl: C, 57.71; H, 3.42; N,19.79. Found:
C, 57.69; H, 3.40; N, 19.77.
4.2.6.17. 3-[(5-(Benzylthio)-1H-tetrazol-1-yl)methyl]-2-chloro-6-
methoxyquinoline 7n. White solid; Yield: 89%, m.p. 134e136 C; IR
(KBr, cm1): 3071 (C-H), 1621 (C]N), 1589 (C]C), 712 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.37 (1H, d, J78 ¼ 8.8 Hz, “H800
ArH), 7.88 (1H, d, J48 ¼ 1.2 Hz, “H400 ArH), 7.51 (1H, d, J57 ¼ 1.4 Hz,
“H500 ArH), 7.49 (1H, dd, J57 ¼ 1.4 Hz and J78 ¼ 8.8 Hz, “H700 ArH),
7.16e7.41 (5H, m, ArH), 6.11 (2H, s, N-CH2), 4.48 (2H, s, CH2 of
benzyl), 3.82 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
158.61, 154.71, 147.88, 145.64, 142.35, 137.48, 130.10, 129.89, 129.81,
129.37, 129.18, 127.21, 123.56, 105.63, 56.97, 54.66, 36.85. Calcd
Mass 397.88 MS (m/z): 399.07 (Mþ2), 397.08 (Mþ). Anal. Calcd for
C19H16N5OSCl: C, 56.32; H, 3.68; N, 18.24. Found: C, 56.29; H, 3.65;
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4.2.6.18. 3-[(5-(Benzylthio)-1H-tetrazol-1-yl)methyl]-2-chloro-6-
methylquinoline 7o. Off white solid; Yield: 76%, m.p. 128e130 C; IR
(KBr, cm1): 3056 (C-H), 1594 (C]N), 1572 (C]C), 711 (C- S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.42 (1H, d, J78 ¼ 8.6 Hz, “H800
ArH), 7.89 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.51 (1H, d, J57 ¼ 1.6 Hz,
“H500 ArH), 7.48 (1H, dd, J57 ¼ 1.59 Hz and J78 ¼ 8.6 Hz, “H700 ArH),
7.12e7.41 (5H, m, ArH), 6.12 (2H, s, N-CH2), 4.55 (2H, s, CH2 of
benzyl), 2.31 (3H, s, CH3). 13C NMR (100 MHz, DMSO-d6, d ppm):
154.82, 149.56, 147.48, 136.81, 136.54, 136.21, 131.45, 130.82, 129.78,
129.55, 129.03, 128.71, 127.55, 126.41, 54.82, 36.80, 23.67. Calcd
Mass 381.88 MS (m/z): 383.08 (Mþ2), 381.08 (Mþ). Anal. Calcd for
C19H16N5SCl: C, 58.77; H, 3.84; N, 19.04. Found: C, 58.76; H, 3.89; N,
19.05.
4.2.6.19. 3-[(5-(Benzylthio)-1H-tetrazol-1-yl)methyl]-6-bromo-2-
chloroquinoline 7p. Yellow solid; Yield: 78%, m.p. 138e140 C; IR
(KBr, cm1): 3065 (C-H), 1618 (C]N), 1593 (C]C), 721 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.56 (1H, d, J78 ¼ 8.6 Hz, “H800
ArH), 7.91 (1H, d, J48 ¼ 1.2 Hz, “H400 ArH), 7.84 (1H, d, J57 ¼ 1.6 Hz,
“H500 ArH), 7.59 (1H, dd, J57 ¼ 1.6 Hz and J78 ¼ 8.6 Hz, “H700 ArH),
7.13e7.46 (5H, m, ArH), 6.11 (2H, s, N-CH2), 4.50 (2H, s, CH2 of
benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm): 154.61, 149.55,
147.60, 136.89, 133.41, 131.48, 130.61, 129.97, 129.62, 129.18, 128.71,
128.45, 127.89, 117.75, 56.42, 36.87. Calcd Mass 446.75 MS (m/z):
448.97 (Mþ4), 446.97 (Mþ2), 444.98 (M). Anal. Calcd for
C18H13N5SBrCl: C, 47.19; H, 2.56; N,16.18. Found: C, 47.20; H, 2.57; N,
16.15.
4.2.6.20. 3-[(5-(Benzylthio)-1H-tetrazol-1-yl)methyl]-2-chloro-6-
ﬂuoroquinoline 7q. Pale yellow solid; Yield: 72%, m.p. 140e142 C;
IR (KBr, cm1): 3060 (C-H), 1591 (C]N), 1567 (C]C), 718 (C-S). 1H
NMR (400 MHz, DMSO-d6, d ppm): 8.59 (1H, d, J78 ¼ 8.4 Hz, “H800
ArH), 8.24 (1H, d, J48 ¼ 0.8 Hz, “H400 ArH), 7.86 (1H, d, J57 ¼ 1.4 Hz,
“H500 ArH), 7.61 (1H, dd, J57 ¼ 1.4 Hz and J78 ¼ 8.4 Hz, “H700 ArH),
7.17e7.48 (5H, m, ArH), 6.08 (2H, s, N-CH2), 4.52 (2H, s, CH2 of
benzyl). 13C NMR (100 MHz, DMSO-d6, d ppm): 154.43, 149.48,
147.81, 136.78, 130.64, 129.81, 129.39, 129.14, 128.85, 128.21, 127.56,
127.32, 121.45, 111.43, 55.71, 36.81. Calcd Mass 385.85 MS (m/z):
387.05 (Mþ2), 385.06 (Mþ). Anal. Calcd for C18H13N5SFCl: C, 54.91;
H, 2.98; N, 18.84. Found: C, 54.89; H, 2.97; N, 18.87.
5. Bioassay conditions
5.1. Molecular docking
5.1.1. DNA ligand docking
The crystal structure used were, (PDB ID: 453D), B-DNA [(50-
D(*CP*GP* CP* GP*AP*AP*TP*TP*CP*GP*CP*G)-3'-benzimidazole
complex)] [61] and solution structure of intrastrand cisplatin-cross
linked DNA octamer (PDB ID: 1AU5), D(CCTG*G*TCC): D(GGA
CCAGG), NMR,minimized average structure [62], obtained from the
Protein Data Bank (www.rcsb.org/pdb). The DNA ﬁle was prepared
for docking by adding polar hydrogen atom with Gasteiger-Huckel
charges and water molecules were removed. The 3D structure of
the ligands was generated by the SKETCH module and was imple-
mented in the SYBYL program (Tripos Inc., St. Louis, USA). The
energy-minimized conformationwas obtained with the help of the
Tripos force ﬁeld using the Gasteiger-Huckel [63] charges. The
molecular docking was performed with the Surﬂex-Dock program
which was interfaced with Sybyl-X 2.0 [64]. Later the other
miscellaneous parameters were assigned to the default values
given by the software.5.1.2. NMT, DHFR docking with ligand
The protein crystal structure ﬁle NMT Aspergillus fumigatus and
DHFR Candida albicans (PDB ID: 4CAW; B-Chain and 1AI9), was
taken from PDB (www.rcsb.org/pdb). The proteins were prepared
for docking by adding polar hydrogen atom with Gasteiger-Huckel
charges and water molecules were removed. The 3D structure of
the ligands was generated by the SKETCH module implemented in
the SYBYL program (Tripos Inc., St. Louis, USA) and its energy-
minimized conformation was obtained with the help of the
Tripos force ﬁeld using Gasteiger-Huckel [63] charges and molec-
ular docking was performed with Surﬂex-Dock program that is
interfaced with Sybyl-X 2.0 [64] and other miscellaneous parame-
ters were assigned with the default values given by the software.5.2. In vitro anticancer screening
All the human tumor cell lines for the cancer screening panel
were grown in RPMI 1640 medium containing 5% fetal bovine
serum and 2 mM l-glutamine. The typical screening experiment is
carried out by inoculating the cells into 96 well microtiter plates in
100 ml with plating densities ranging from 5000 to 40,000 cells/
well, which depends on the doubling time of individual cell lines.
After inoculation, the microtiter plates were incubated at 37 C, 5%
CO2, 95% air and 100% relative humidity for 24 h prior to addition of
experimental drugs. After 24 h, two of the plates of each cell line
were ﬁxed in situ with TCA, to represent the measurement of the
cell population for each cell line at the time of drug addition (Tz).
Experimental drugs were solubilized in dimethyl sulfoxide at
around 400-folds and the desired ﬁnal maximum test concentra-
tion was stored frozen prior to use. At the time of drug addition, an
aliquot of frozen concentrate is defrosted and diluted to twice the
desired ﬁnal maximum test concentration with the complete me-
dium containing 50 mg/ml Gentamicin. An additional, 10-fold of
serial dilutions were added to a total of ﬁve drug concentrations
plus control. Aliquots of 100 ml of these different drug dilutions
were added to the appropriatemicrotiter wells, containing 100 ml of
medium, resulting in the required ﬁnal drug concentrations.
Following drug addition, all the plates were incubated for an
additional 48 h at 37 C, 5% CO2, 95% air, and 100% relative humidity.
For adherent cells, the assay was terminated by the addition of cold
TCA. Cells were ﬁxed in situ by the gentle addition of 50 ml of cold
50% (w/v) TCA (ﬁnal concentration, 10% TCA) and incubated for
about 60min at 4 C. The supernatant was discarded, and the plates
were washed ﬁve times with tap water and air dried. Sulforhod-
amine B (SRB) solution (100 ml) at 0.4% (w/v) in 1% acetic acid was
added to each well, and the plates were incubated for 10 min at
room temperature. After staining, unbound dye was removed by
washing ﬁve times with 1% acetic acid and the plates were air dried.
Bound stain was thoroughly solubilized with 10 mM trizma base,
and the absorbance was read on an automated plate reader at a
wavelength of 515 nm. For suspension cells, the methodology was
the same except that the assay was terminated by ﬁxing settled
cells at the bottom of the wells by adding 50 ml of 80% TCA (ﬁnal
concentration, 16% TCA). Using the seven absorbance measure-
ments [time zero, (Tz), control growth, (C), and test growth in the
presence of drug at the ﬁve concentration levels (Ti)], the per-
centage growth is calculated at each of the drug concentrations
levels. Percentage growth inhibition is calculated as:
½ðTi TzÞ=ðC  TzÞ  100 for concentrations for which Ti> =
¼ Tz
½ðTi TzÞ=Tz  100 for concentrations for which Ti< Tz
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experimental agent. Growth inhibition of 50% (GI50) was calculated
from [(Ti-Tz)/(C-Tz)]  100 ¼ 50, which the drug concentration
resulting in a 50% reduction in the net protein increase (as
measured by SRB staining) in control cells during the drug incu-
bation. The drug concentration resulting in total growth inhibition
(TGI) was calculated from Ti ¼ Tz. The LC50 (concentration of drug
resulting in a 50% reduction in the measured protein at the end of
the drug treatment as compared to that at the beginning) indicating
a net loss of cells following treatment was calculated from [(Ti-Tz)/
Tz]  100 ¼ 50. Values were calculated for each of these three
parameters if the level of activity was reached; however, if the ef-
fect was not reached or exceeded, the value for that parameter was
expressed as greater or less than the maximum or minimum con-
centration tested [65,66].
5.3. In vitro antifungal activity
The title compounds were evaluated for their in vitro antifungal
activity with C. albicans and A. fumigatus (cultured) by Disc Diffu-
sion Method [67] with Sabouraud agar medium. Fluconazole was
used as a reference drug. Each compound was tested at a concen-
tration of 100 mg/ml in DMSO. The zone of inhibition (mm) was
measured at 37 C. Brieﬂy, agar (pH¼ 7.2e7.4) was placed into Petri
dish (100 mm size and 4 mm depth). The agar plates were then
inoculated with broth cultures diluted to McFarland 0.5 turbidity. A
disc containing known amounts of a compound to be analyzed was
placed on the surface of an agar plate that has been inoculated with
a standardized suspension of microorganisms to be tested. Paper
discs with only DMSO (tests involving Fluconazole) were used as
negative controls. All experiments were conducted in triplicate and
repeated if the results differed.
Dilutions of each drug have to be done with BHI for MIC [68]. In
the initial tube 20 mL of drugwas added into the 380 mL of BHI broth.
For dilutions 200 mL of BHI broth was added into the next 9 tubes
separately. Then from the initial tube 200 mL was transferred to the
ﬁrst tube containing 200 mL of BHI broth. This was considered as
101 dilution. From 101 diluted tube 200 mL was transferred to
second tube to make 102 dilution. The serial dilutionwas repeated
up to 109 dilution for each drug. From the maintained stock cul-
tures of required organisms, 5 mL was taken and added into BHI
(2 mL) broth. In each serially diluted tube 200 ml of above culture
suspension was added. The tubes were incubated for 24 h and
observed for turbidity. The MIC values were obtained from the
lowest concentration of the test compounds where the tubes
remained clear indicating that the bacterial or fungal growth was
completely inhibited at this concentration.
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